Indication
Relapsing Remitting Multiple Sclerosis
Stage
Phase II
Location of Study
Europe
24 trial sites in 6 countries
Description
The MINDSET-01 clinical trial is a fifteen month, double-blind, placebo-controlled trial. The trial will be followed by a 12 month active treatment open label extension period. The objectives of the study are to demonstrate safety and efficacy of dirucotide versus placebo as measured by relapse rate, MRI activity and disease progression.
Status
This trial has completed. For futher information please click here.